Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2000, p. 8590-8601, Vol. 20, No. 22
Department of Biomolecular Chemistry,
University of Wisconsin
Received 20 July 2000/Accepted 17 August 2000
The matrix (M) protein of vesicular stomatitis virus (VSV) is a
potent inhibitor of bidirectional nuclear transport. Here we
demonstrate that inhibition occurs when M protein is in the nucleus of
Xenopus laevis oocytes and that M activity is readily reversed by a monoclonal antibody ( Trafficking of large macromolecules
(more than 50 kDa) between the nucleus and the cytoplasm occurs through
nuclear pore complexes (NPCs) via signal-dependent, carrier-mediated
processes (reviewed in references 39 and
54). This transport is subject to control in
response to a variety of stimuli such as progression through the cell
cycle, exposure to stress, and infection by viruses (reviewed in
reference 39). Thus, control of nucleocytoplasmic
transport is an important element in the regulation of gene expression.
Much of the carrier-mediated movement through NPCs requires
cargo-specific transport receptors called importins and exportins (or
karyopherins), which are members of the importin Directionality of nuclear transport appears to be governed largely by
Ran, a small GTPase that is a central component of most known
nucleocytoplasmic transport pathways (reviewed in references 9 and 41). Owing to the
asymmetric localization of the Ran effector proteins RanGAP (the GTPase
activating protein in the cytoplasm) and RCC1 (the guanine nucleotide
exchange factor in the nucleus), a steep concentration gradient of
RanGTP is presumed to exist across the nuclear envelope
(29). This gradient plays a pivotal role in
nucleocytoplasmic transport by triggering both assembly and disassembly
of receptor-cargo complexes in the appropriate subcellular compartment
(60). Thus, import complexes assemble in the cytoplasm in
the absence of RanGTP and disassemble in the nucleus in the presence of
RanGTP, whereas export complexes form upon binding to RanGTP in the
nucleus and dissociate upon removal and hydrolysis of RanGTP in the
cytoplasm. Consequently, collapse of the RanGTP-GDP gradient leads to a
block of most nucleocytoplasmic transport (29).
Nucleocytoplasmic transport is subject to regulation during infection
by many types of viruses. For example, the NS1 protein of influenza
virus inhibits export of cellular poly(A)+ mRNA
(7). Expression of the Rev protein of human immunodeficiency virus type 1, which functions as an adapter for CRM1, allows export of
incompletely spliced viral mRNAs (14, 17, 25, 38). The E1B
oncoprotein of adenovirus type 5 promotes export of viral mRNAs and
inhibits export of most cellular mRNA species (11). The
matrix (M) protein of vesicular stomatitis virus (VSV) inhibits bidirectional nuclear transport of both RNAs and proteins
(27).
Infection of cells by VSV, a negative-strand RNA virus that replicates
in the cytoplasm, results in rapid shutoff of cellular gene expression
(59) and snRNA processing (18). The M protein, a
major structural component of the VSV virion, plays a central role both
in the inhibition of host cell gene expression (5, 42) and
in viral assembly (59). These two properties are genetically separable from each other (6, 8, 37) in that methionine 51 (Met-51) of the M protein is required for inhibition of host cell gene
expression, but not for viral assembly, whereas amino acids 4 to 21 are
needed for viral assembly but not for inhibition of host cell gene expression.
Previously, we showed that M protein synthesized in Xenopus
laevis oocytes inhibits the import of snRNPs and karyophilic
proteins, as well as the export of snRNAs and mRNAs, but not tRNAs
(27). Here we use a monoclonal antibody that recognizes M
protein ( DNA templates and in vitro RNA synthesis.
DNA templates for
transcription of RNA import or export substrates were generated either
by PCR amplification (U1, U1Sm DNA templates and in vitro synthesis of M protein mRNA.
DNA
templates for synthesis of polyadenylated mRNAs encoding
histidine-tagged wild-type,
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Matrix Protein of Vesicular Stomatitis Virus
Inhibits Nucleocytoplasmic Transport When It Is in the Nucleus and
Associated with Nuclear Pore Complexes
Madison, Madison, Wisconsin 53706-1532
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
M). We identify a region of M
protein, amino acids 51 to 59, that is required both for inhibition of
transport and for efficient recognition by
M. When expressed in
transfected HeLa cells, M protein colocalizes with nuclear pore
complexes (NPCs) at the nuclear rim. Moreover, mutation of a single
amino acid, methionine 51, eliminates both transport inhibition and
targeting to NPCs. We propose that M protein inhibits bidirectional
transport by interacting with a component of the NPC or an
NPC-associated factor that participates in nucleocytoplasmic transport.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
superfamily of
proteins (16, 21, 45, 61). Transport receptors can bind
their cargoes either directly or via specialized adapter proteins. For
example, importin
mediates import of proteins containing basic
nuclear localization sequences and small nuclear ribonucleoproteins
(snRNPs) using the adapter proteins importin
(1) and
snurportin (28, 43), respectively. Importin
can also
interact directly with import cargoes, such as cyclin B (40,
53) and certain ribosomal proteins (30). CRM1
(Exportin1) mediates the export of proteins containing leucine-rich
nuclear export signals (NES) as well as unspliced viral mRNAs and
pre-snRNAs that are bound to specific NES-containing adapter proteins
(14, 17, 51, 57). Exportin-t binds directly to its RNA
export cargo, tRNA (3, 33).
M) to investigate the mechanism of this inhibition of
bidirectional nuclear transport. We demonstrate that inhibition of both
export and import is readily reversed by this antibody and that M
protein works from within the nucleus. Furthermore, we show that Met-51 and the adjacent residues 52 to 59 are necessary both for efficient recognition by
M and for the inhibition of nuclear transport. Met-51
is also important for colocalization of M protein and NPCs, indicating
that the interaction between M protein and an NPC-associated factor(s)
is necessary for M activity.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
, U5, and U6 snRNAs,
U3 snoRNA, and NL-15 RNA) or by linearization of plasmid DNAs (AdML
pre-mRNAs and tRNA) as described previously (22, 44, 55). In
vitro synthesis of [
-32P]GTP-labeled RNAs was
performed in 20-µl reactions using SP6 polymerase (U1,
U1Sm
, U5, U3, and AdML RNAs) or T7 polymerase (tRNA
and NL-15 and U6 RNAs) as detailed elsewhere (44). U1,
U1Sm
, U5, U3, and AdML RNAs were synthesized with
m7GpppG caps, whereas U6 received a
mepppG cap. All RNAs
were purified as described previously (55).
2-46,
4-21, and
199-229 M
proteins were generated by PCR amplification (see Table 1). Following PCR, the DNA products were cleaved with the appropriate restriction enzymes and cloned into the pSP64poly(A) vector (Promega). DNA templates for synthesis of mRNAs encoding histidine-tagged internal deletions
47-75,
116-175, and
155-185 of M protein were
constructed using site-directed mutagenesis (Clontech). A mutagenic
primer (Table 1) complementary to regions
flanking the deletion and a selection primer were annealed to the DNA
template, pSP64.OMHis6 (Table 1). The primers were extended using the
Klenow fragment of DNA polymerase, and the DNAs were ligated and
transformed into Escherichia coli BMH 71-18 muts
cells. A DNA template for synthesis of mRNA encoding a histidine-tagged
internal deletion (
75-106) of M protein was obtained by digestion
of pSP64.OMHis6 DNA (Table 1) with BglII, which removed a
fragment encoding a region within the M protein corresponding to amino
acids 75 to 106. The remaining large DNA fragment was blunt ended with
deoxynucleoside triphosphates using T4 DNA polymerase, gel purified,
and recircularized using T4 DNA ligase; the ligated DNA was transformed
into E. coli JM109 cells. The pSV2-O82M plasmid, encoding M
protein with the M51R mutation (6), was kindly provided by
Douglas Lyles (Wake Forest University). The HindIII
fragment of this DNA containing the O82M coding region was ligated to
HindIII-cut pSP64poly(A)+ vector DNA and
transformed into E. coli DH5
cells. The nucleotide sequences of all clones were confirmed by DNA sequencing.
TABLE 1.
Plasmid constructions
Construction of GFP-M DNAs. To make plasmids encoding chimeric green fluorescent protein (GFP)-M fusion proteins [pEGFP-C1-OM and pEGFP-C1-OM(51R)], the BamHI fragment containing the M protein gene from either the pGEX-2T-OM or the pGEX-2T-OM(51R) plasmid (see below) was ligated to BamHI-cut pEGFP-C1 (Clontech) DNA and transformed into E. coli cells. The correct orientations of the M protein genes were confirmed by digestion of the resulting plasmid DNAs with BglII.
DNA transfections. For transient transfections of GFP-M DNAs into cells, a six-well tissue culture plate containing coverslips was seeded with 4 × 105 HeLa cells per well 24 h before use. Transfections were carried out according to the protocol of Life Technologies, Inc., using 1 µg of pEGFP-C1-OM or of pEGFP-C1-OM(51R) DNA and 10 µl of Lipofectamine (Life Technologies, Inc.). After 24 h the cells were processed for immunofluorescence.
Construction of GST-M protein DNAs and purification of GST-M proteins. The pGEX-2T-OM vector encoding a glutathione S-transferase (GST)-M fusion protein, GST-M, was generated by PCR amplification (see Table 1). The upstream primer contained two nucleotide changes at positions 4 and 6 with respect to the nucleotide sequence of M protein (Orsay strain). These changes, which generated a BamHI restriction site, resulted in a serine-to-glycine substitution at amino acid 2. The PCR product and the GST encoding expression vector, pGEX-2T (Pharmacia), were digested with BamHI, ligated together, and transformed into JM109 cells.
To generate pGEX-2T-OM(51R), the pSP64-O82Mpoly(A) and pGEX-2T-OM plasmid DNAs were digested with MfeI and StuI. The fragment released from the region of pSP64-O82Mpoly(A) encoding M protein was gel purified and ligated into the cut pGEX-2T-OM vector, which was then transformed into JM109 cells. The plasmids pGEX-2T-OM(AAA48 through AAA63), pGEX-2T-OM(51A), and pGEX-2T-OM(51L) were generated by two-step PCR (Table 1). PCR products were digested with MfeI and StuI and ligated into the similarly cut vector, pGEX-2T-OM. pGEX-OM(48-62), encoding amino acids 48 to 62 of M protein fused to the C terminus of GST, was made by ligation of complementary oligonucleotides containing the appropriate ends with pGEX-2T plasmid DNA linearized with the same restriction enzymes. For production of recombinant proteins, all plasmids were transformed into E. coli BL21 cells. Cells were grown overnight at 37°C in Luria-Bertani medium containing ampicillin and then induced for 3 hours with 1 mM IPTG. Cells were harvested by centrifugation, resuspended in one-tenth volume of 1× phosphate buffered saline (PBS; pH 7.4)-1 mM dithiothreitol-1% Triton X-100-1 mM phenylmethylsulfonyl fluoride and immediately lysed by passage through a French press. The lysates were clarified by centrifugation, made 10% with respect to glycerol, and frozen at
70°C until further purification.
For affinity purification of GST-M proteins, lysates (10 ml) were
quick-thawed and loaded directly onto a 1-ml glutathione-Sepharose column (Sigma). Columns were washed with 10 ml of wash buffer (PBS, pH
7.4; 1 M NaCl; 1% Triton X-100) and eluted with 50 mM Tris-HCl (pH
8.0)-5 mM glutathione-150 mM KCl-0.01% Triton X-100. Then, 0.5-ml
fractions were collected, and aliquots were analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Fractions
containing GST-M protein were pooled, made 10% with respect to
glycerol, and stored at 4°C or frozen at
70°C until use.
Analysis of RNA transport in X. laevis oocytes. Stage VI oocytes were manually dissected from X. laevis ovaries and maintained in MBS-H medium at 18°C (24). Nuclei or cytoplasms were injected with 12 nl of H2O containing ~5 fmol each of 32P-labeled RNAs, along with blue dextran (44, 55). After incubation at 18°C for the indicated times, oocytes were manually dissected and analyzed as previously described (22, 35, 44).
For injection of mRNA encoding the wild-type VSV M protein, 25 nl (~20 fmol) was injected into the cytoplasm ~18 h prior to the injection of import or export RNAs. For injections of mRNAs encoding M deletion proteins, 25 nl (~200 fmol) was injected. For injection of purified GST-M proteins (~100 µg/ml), 15 nl was injected into the nucleus or 25 nl was injected into the cytoplasm. For injection of GST-M(48-62) protein, the concentration of protein in the injection mix was 3.6 mg/ml. When GST-M protein and antibodies were coinjected, the concentration of GST-M protein in the injection mixes was ~25 µg/ml. For inhibition of protein synthesis, cycloheximide was added directly to the MBS-H medium at a final concentration of 200 µg/ml.Analysis of protein synthesis in X. laevis oocytes. Stage VI oocytes were injected into the cytoplasm with mRNAs for M proteins and incubated for 16 to 24 h in MBS-H containing 0.5 to 1.0 µCi of [35S]methionine (Amersham) (24). The nuclear and cytoplasmic fractions from such oocytes were analyzed as previously described (27, 46).
Antibodies.
The hybridoma cell line synthesizing the
M
monoclonal antibody (23H12) (36) was kindly provided by
Douglas Lyles (Wake Forest University). Antibodies were purified from
hybridoma supernatants on a protein G-Sepharose (Pharmacia) column
using standard procedures (26). Antibodies were stored at
20°C until use. For use in oocytes,
M was concentrated to 27 mg/ml (Amicon), and 15 nl (nucleus) or 25 nl (cytoplasm) was injected.
The nonimmune rabbit anti-mouse immunoglobulin G (IgG) antibody
(Cappell) was concentrated to 22 mg/ml (Amicon) and either 15 nl
(nucleus) or 25 nl (cytoplasm) was injected into oocytes. The
monoclonal
GST antibody (Pharmacia) was dialyzed against PBS at 0.2 mg/ml. For coinjection of
M or
GST antibody and GST-M protein,
the concentration of antibody in the injection mixtures was ~0.18
mg/ml.
Western blotting and immunoprecipitations. For Western blot analysis, purified GST-M proteins or oocyte extracts were fractionated by SDS-PAGE and the proteins were transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore). Membranes were probed with antibodies in TBS-T (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1 mM EDTA; 0.25% Tween 20) containing 5% powdered milk (Carnation) and developed with LumiGLO (Kirkegaard and Perry).
For immunoprecipitations, 9 µg of
M was coupled to 20 µl of
protein A-Sepharose beads (Sigma) in TBS-T for 2 h at 4°C.
Either 40 ng of recombinant M protein or 0.5 oocyte equivalent of
[35S]methionine-labeled cytoplasmic extract, prepared
from oocytes expressing M protein, was added to the
M beads. After
overnight rotation at 4°C, the supernatant was collected and the
pellets were washed five times with 500 µl of TBS-T. The supernatant
and pellet fractions were visualized by SDS-PAGE, followed by autoradiography.
Immunofluorescence. To process cells for immunofluorescence, cells were either fixed with 2% paraformaldehyde for 15 min followed by permeabilization with 0.5% Triton X-100 or else extracted first with 0.5% Triton X-100 for 3 min, followed by paraformaldehyde fixation. GFP-M proteins were visualized using the ×100 objective of an Axioplan 2 fluorescence microscope (Zeiss). For double-labeling experiments, GFP-M protein expressing cells were extracted with Triton X-100, fixed with formaldehyde, and incubated with 5 µg of mAb414 (kindly provided by Laura Davis, Brandeis University). The subsequent incubation was with Alexa 568-conjugated goat anti-mouse secondary antibody (Molecular Probes).
Phage display.
Isolation of peptides that could be
recognized by the
M antibody (23H12) was done by phage display as
described previously (49). The CW1 M13 phage library, a
12-mer random peptide library, was kindly provided by Brian Kay
(University of Wisconsin
Madison). After three rounds of selection,
the resulting phage were plaque purified. Binding activities of the
cloned phage were confirmed by enzyme-linked immunosorbent assay, and
the peptide sequences of isolated
M binding phage were deduced from
DNA sequence analysis.
| |
RESULTS |
|---|
|
|
|---|
M antibody in either the nucleus or the cytoplasm reverses the
inhibitory activity of M protein.
The M protein of VSV is a potent
inhibitor of bidirectional nuclear transport (27). As we
reported previously, export of RNAs (snRNA and mRNA but not tRNA) from
oocyte nuclei is selectively blocked upon the synthesis of M protein
following cytoplasmic injection of in vitro-transcribed M protein mRNA
(Fig. 1A, panel c). M protein also
inhibits the import of karyophilic proteins (27;
data not shown) and several RNAs, such as U1, U5, and U6 snRNAs and
NL-15 RNA (Fig. 1C, panel d), which use different import pathways
(22). U3 snoRNA, which normally is not exported
(56) or imported (50), was included here as a
control for accuracy of injection and dissection of the oocytes.
|
M) (36). We first showed that
M can
neutralize M activity by introducing
M into the cytoplasm of oocytes
prior to the injection of M mRNA (Fig. 1A). The presence of this
antibody in the cytoplasm eliminated the inhibitory activity of the
newly synthesized M protein (panel d). As expected, RNA export in
oocytes containing no M mRNA was unaffected by cytoplasmic (panel b) or
nuclear
M antibody (data not shown). The ability to neutralize M
activity was specific to
M since injection of nonspecific IgGs into
the cytoplasm (panel e) was without effect.
We then asked if
M could reverse M activity once the inhibition of
transport had been established in oocytes expressing M protein (Fig. 1B
and C). Inhibition of export of both mRNA and snRNA (Fig. 1B) was
reversed regardless of whether
M was injected into the cytoplasm
(panel a) or the nucleus (panel b). RNA import (Fig. 1C) also was
restored by
M, independent of where the antibody was introduced
(panels d to f); again, the antibody had little or no effect on RNA
import in the absence of M protein (panels b and c). Likewise, protein
import was restored by
M that was injected into either the nucleus
or the cytoplasm (data not shown). Thus,
M in either the nucleus or
the cytoplasm can reverse M activity, raising the possibility that M
protein functions in the nucleus.
M antibody eliminates M activity by nuclear depletion or
neutralization of M protein.
To determine how
M neutralizes M
activity, we monitored the intracellular distribution of M protein in
the presence and absence of
M (Fig.
2A). Because of its small size (~28
kDa), M protein might be able to enter and exit the nucleus either by
diffusion or by carrier-mediated transport. In the absence of the
antibody, M protein was present in both the nucleus and the cytoplasm
(27) (Fig. 2A, lanes 1 and 4). Independent of the expression
of M protein,
M antibody remained in the cell compartment into which
it was introduced (Fig. 2A, lanes 5 and 6; see also Fig. 2B, lanes 2 and 3). Injection of
M into the cytoplasm prior to injection of M
mRNA led to sequestration of M protein in the cytoplasm (Fig. 2A, lanes
3 and 6), showing that complexes of M protein plus
M do not transit
the NPCs (Fig. 2A, lane 6; Fig. 2B, lanes 2 and 3). Thus,
neutralization of M activity by cytoplasmic
M (Fig. 1A) is due
either to the formation of antibody-M protein complexes in the
cytoplasm or to the lack of M protein in the nucleus.
|
M also reversed M activity after transport had already been
established (Fig. 1B and C), we analyzed the distribution of M protein
in such oocytes (Fig. 2B). Injection of
M into the cytoplasm
resulted in the nuclear depletion of M protein (lanes 1 and 3),
indicating that the nuclear M protein either exits to the cytoplasm or
turns over. Injection of
M into the nucleus led to increased levels
of nuclear M protein but did not deplete the cytoplasmic pool (lanes 2 and 4), presumably because of continued synthesis of M protein. The
fact that transport in these oocytes was normal indicates either that
this cytoplasmic M protein is in an inactive form or that the target of
M protein resides in the nucleus. In any case, the elimination of M
activity (Fig. 1) correlates with the lack of free M protein in the
nucleus, due to binding of
M to M protein in the nucleus, nuclear
turnover, or sequestration of the protein in the cytoplasm. Therefore,
we propose that M protein inhibits nuclear transport from within the nucleus.
Inhibition of nuclear transport occurs from within the
nucleus.
To introduce M protein directly into the nucleus (or the
cytoplasm), we generated a fusion protein containing GST and M protein (GST-M protein). This recombinant protein had a molecular weight of
about 56,000, thereby reducing its rate of passive diffusion through
NPCs (54). Upon injection into either the nucleus or the
cytoplasm, GST-M protein was stable, and it gradually distributed between both compartments over a 20-h period (Fig.
3A). Injected recombinant GST-M protein
inhibited both import of RNAs (Fig. 3B) and export of
U1Sm
RNA (Fig. 3C, panels b and d) and AdML mRNA
(Fig. 4b). Moreover, the inhibitory
activity was independent of whether the protein was injected into the
nucleus (Fig. 3B, panel b; Fig. 3C, panel b) or the cytoplasm (Fig. 3B, panel c; Fig. 3C, panel d).
|
|
M was present in either the nucleus or the cytoplasm (Fig.
3C, panels e and f). Therefore, we tested our model that M protein acts
from within the nucleus by injecting GST-M protein into the nucleus and
M into the cytoplasm. When transport was monitored 1 h after
injection of RNA substrates, GST-M protein inhibited RNA export (panel
c), demonstrating that nuclear M protein is sufficient for M activity.
At later times, this GST-M activity was attenuated (data not shown),
consistent with our previous finding that cytoplasmic
M eliminates M
activity by sequestering M protein as it exits the nucleus (Fig. 1B and 2B). We conclude that GST-M protein functions from within the nucleus
to inhibit nuclear transport.
Nuclear M protein operates efficiently.
Only a low level of
cytoplasmically injected GST-M protein appeared in the nucleus within
1 h (Fig. 3A), but this was sufficient for M activity (Fig. 3C,
panel d). To determine the amount of nuclear GST-M protein required for
inhibition of U1Sm
RNA export, we varied the amount
of protein injected. About 2 × 109 molecules (~200
pg) per oocyte nucleus sufficed (Fig. 4b), but 100 pg did not (panel
c). Because it is unlikely that all of the recombinant protein
molecules were active, 200 pg of GST-M protein represents an upper
limit of the amount required.
RNA was exported within the first hour compared
to 50% of the RNA in the absence of GST-M protein. Thus, M protein
functions very quickly within the nucleus to inhibit transport.
Nuclear
M antibody reverses inhibition by shielding a region
necessary for M activity.
Since reversal of transport inhibition
by nuclear
M, in principle, could be due to the synthesis of new
protein(s) required for transport, we tested if
M could restore
transport in the absence of protein synthesis. Inhibition of RNA export
by GST-M protein was reversed by nuclear
M, even in the presence of
cycloheximide (Fig. 3D), demonstrating that M activity does not involve
the irreversible modification or destruction of a component that
participates in nuclear transport. Also, the neutralization of GST-M
protein by
M was dependent on binding of the monoclonal antibody to
its specific epitope, since a GST-specific monoclonal antibody (
GST) did not interfere with the activity of GST-M protein (data not shown).
Thus,
M may reverse transport inhibition by binding to a region of M
protein necessary for M activity, thereby disrupting interactions
between the protein and its target(s).
Met-51 of M protein contributes to recognition by
M
antibody.
The region of M protein recognized by
M was
identified by Western blot analysis of mutant M proteins. Several mRNAs
encoding deletion mutants of M protein were generated, and the proteins were expressed in oocytes, as demonstrated by labeling with
[35S]methionine (Fig. 5A,
top panel). All of these mutant M proteins, except for the
47-75
deletion protein, were recognized by
M (bottom panel). In addition,
an M13 phage library displaying random peptides 12 amino acids in
length was screened for the ability to be recognized by
M. A
consensus sequence present in seven of the nine selected peptides,
DPNQ, is present once in the immunizing antigen (M protein of the San
Juan strain) (data not shown). This sequence is very similar to the
amino acid sequence, DPHQ, found at the same position (amino acids 55 to 58) of the M protein (Orsay strain) used here (Fig. 5D). Thus, the
M epitope is contained within amino acids 47 to 75 of M protein and
includes residues 55 to 58.
|
M epitope, we tested if this residue is important for
recognition by
M. GST-M(51R) mutant protein reacted poorly with
M
in Western blots (Fig. 5B, top panel, lane 2), a result consistent with
the unpublished results of others analyzing tsO82 mutant M
protein synthesized in mammalian cells (D. Lyles, personal communication). Also, the native M(51R) protein was recognized inefficiently by
M in an immunoprecipitation assay (Fig. 5C, compare
lanes 2 and 3 with lanes 5 and 6).
Since the M51R mutation introduces a positively charged residue at
position 51, we asked if a conservative substitution of Met-51 with the
hydrophobic residues leucine or alanine could maintain
M
recognition. In Western blots, the GST-M(51L) but not the GST-M(51A)
protein was recognized like wild-type GST-M protein (Fig. 5B, top
panel, lanes 3 and 4). Thus, an amino acid with a long aliphatic side
chain is required at position 51 of M protein for efficient binding to
M.
Met-51 is essential for M activity.
To test if the
M
epitope region is also required for inhibition of nuclear transport, we
assayed the effect of the M51R mutation on M activity. GST-M(51R)
protein injected into the nucleus was unable to inhibit RNA
export (Fig. 6A), showing that an
arginine at position 51 of M protein eliminates M activity. Inhibition of transport was not observed even when the amount of injected mutant
protein was 50 times that needed for inhibition by wild-type GST-M
protein (cf. Fig. 4). Also, M(51R) protein was inactive for inhibition
of protein import (data not shown). Western blot analysis, using
GST
antibody, demonstrated that the protein was stable in oocytes and that
its distribution was similar to that of GST-M protein (Fig. 6B). Thus,
the Met-51 to Arg-51 mutation abolishes the ability of M protein to
inhibit both nuclear transport and gene expression (6, 13,
52), showing that the mechanisms of inhibition of these processes
are closely linked.
|
M, it does not suffice for M
activity, showing that a methionine at position 51 is essential for the
inhibition of nuclear transport.
Amino acids 51 to 59 are necessary, but not sufficient, for
inhibition of transport by M protein.
Secondary structure
predictions by the PhD and PREDATOR algorithms (19, 20, 47)
suggest that the
M epitope is contained within a region of M protein
(50-EMDTHDPHQ-58) that is likely to be in either a loop or a turn
structure. This region probably is exposed on the surface of the
protein because most of these amino acids are hydrophilic and
M can
bind and inactivate M protein in vivo. This model is in agreement with
previous findings by others demonstrating that a major V8 protease
cleavage site in M protein occurs at position 50 (31).
M (Fig.
7A), a result consistent with our
M
epitope mapping (Fig. 5). When tested for their abilities to inhibit
transport, the same three mutant GST-M proteins were inactive, even
though they were stable and distributed similarly to the GST-M protein
in injected oocytes (Fig. 7A). Thus, in addition to Met-51, amino acids
52 to 59 are necessary for both
M recognition and GST-M activity.
|
M in
immunoprecipitations (Fig. 7B), showing that the
M epitope region
was presented in a context resembling that of the native M protein.
Although a large nuclear pool of this protein remained for at least
18 h after injection into oocytes (data not shown), it had no
effect on the export of mRNA or snRNAs (Fig. 7C). Thus, amino acids 51 to 59 are necessary, but not sufficient, for M activity.
Met-51 is necessary for targeting M protein to the nuclear
rim.
To determine where within the nucleus M protein might
function, GFP-tagged wild-type and mutant [M and M(51R)] proteins
were expressed in transiently transfected HeLa cells. A comparable recombinant GFP-tagged M protein inhibited nuclear transport upon injection into oocytes (data not shown). The wild-type GFP-M protein localized to the nucleoplasm, the cytoplasm, and the nuclear rim (Fig.
8A, panel a). In contrast, the M(51R)
mutant protein showed only nucleoplasmic and cytoplasmic localization;
no nuclear rim association was readily observable (panel b), indicating
that the intracellular distribution of the inactive M protein differs from that of wild-type M protein.
|
| |
DISCUSSION |
|---|
|
|
|---|
We have demonstrated here that the M protein of VSV must be in the
nucleus to inhibit bidirectional nuclear transport and that the target
of M protein is likely to be a component of the NPC. Our results show
that inhibition of transport is readily reversible, since a monoclonal
antibody (
M) can restore transport, even after inhibition has been
established. Amino acids 51 to 59 of M protein are important both for
the inhibition of nuclear transport and for recognition by
M.
Moreover, we have identified a single amino acid, Met-51, that is
necessary for the association of M protein with the nuclear rim. We
propose that interaction of M protein with a nuclear component(s) of
the NPC and/or an NPC-associated factor(s) is responsible for its
inhibition of nuclear transport.
Our results show that M protein must be in the nucleus, and not
complexed with
M, in order to inhibit nucleocytoplasmic transport. Transport is restored either when the activity of M protein is neutralized by nuclear
M or when M protein is sequestered and neutralized in the cytoplasm by
M (Fig. 1 and 2). Moreover, GST-M protein introduced into the nucleus inhibits transport, even when neutralizing
M antibody is present in the cytoplasm (Fig. 3C). Consistent with the need for a pool of nuclear GST-M protein, GST-M
activity dissipates with time as the protein is depleted from the
nucleus and sequestered by
M in the cytoplasm. Thus, M protein
exerts its inhibitory effect from within the nuclear compartment.
The interaction of M protein with a nuclear target(s) must be rapid,
since inhibition of transport occurs soon after delivery of M protein
to the nucleus. Also, this association must be dynamic, since
M can
restore transport even when protein synthesis is blocked (Fig. 3D),
ruling out resynthesis of targets as a way to restore transport. Thus,
M protein may modulate the activity of a nuclear transport factor
through reversible modification (e.g., phosphorylation, ADP
ribosylation, etc.). Alternatively, M protein could disrupt
associations between factors that participate in nuclear transport by
competitively binding to one of them.
The M(51R) mutant protein, originally identified in a spontaneous
temperature-sensitive mutant of VSV (tsO82) (8),
inactivates the ability of M protein to inhibit transport (Fig. 6A) and
affects binding to
M (Fig. 5B). Conservative substitution of Met-51
with either leucine or alanine also eliminates M activity (Fig. 6B), demonstrating that a methionine at this position is essential for the
inhibitory effect of M protein. In the case of GST-M(51L) protein, its
inactivity cannot be attributed to gross misfolding of the epitope
region, since
M recognition is not altered by this mutation (Fig.
5B). We propose that Met-51 of M protein is necessary for the
interaction between M protein and its target(s) and that binding of
M to the epitope region of M protein disrupts this association.
Met-51 lies within a region of M protein (amino acids 50 to 58)
predicted to form an exposed loop or turn structure. Triple alanine
scanning mutations of the adjacent amino acids in this presumptive loop
region (amino acids 52 to 59) abolished both M activity and recognition
by
M (Fig. 7A). However, substitution of amino acids 53 to 59 of M
protein with a sequence composed of both hydrophilic and hydrophobic
amino acids, which are less likely than consecutive alanine residues to
distort the structure of this region, did not eliminate M activity
(unpublished data). This raises the possibility that amino acids 53 to
59 within the loop region do not play a direct role in the interaction
of M protein and its target. We are currently testing precisely which amino acids in this region are involved in essential contacts between M
protein and its nuclear target(s).
Our analyses of the intracellular localization of wild-type and mutant M proteins (Fig. 8) indicate that the nuclear components of the NPC and associated transport factors are likely targets for inactivation by M protein. In transiently transfected HeLa cells, GFP-M protein associated with the nuclear rim, and this localization was coincident with that of FG-repeat containing nucleoporins. In contrast, the nonfunctional mutant GFP-M(51R) protein did not colocalize with NPCs, leading to the model that M protein is associated with the NPC when it inhibits transport.
In support of this model, the pattern of inhibition by M protein
resembles that observed when the activities of specific nucleoporins or
transport factors are inhibited by antibodies or dominant-negative mutant proteins. Antibodies to Nup98 or Nup153, two intranuclear components of the NPC, block the export of mRNA and snRNA, but not tRNA
(46, 58). Likewise, the isolated nucleoporin binding domains
of the transport factors, importin
and TAP, act as
dominant-negative mutants to inhibit the export of mRNA and snRNA and,
to a much lesser extent, tRNA (4, 32). The dominant-negative
form of importin
is also an efficient inhibitor of protein import
(32). Both the antibodies and dominant-negative mutants are
proposed to inhibit NPC function by blocking docking sites for
transporters and their respective cargoes. We propose that M protein
functions in a similar manner to inhibit bidirectional nuclear
transport. Consistent with this proposal, mAb414, which inhibits the
export of most classes of RNAs (23), does not block the
export of ET202, an RNA that was selected solely for its ability to be
exported in the presence of M protein (23).
VSV replicates its genome in the cytoplasm and does not require nuclear factors for virus production (15); nonetheless, M protein can be detected in the nuclei of VSV-infected cells (36). In agreement with that observation, we have shown that M protein distributes to both the cytoplasm and the nucleus in Xenopus oocytes and in transfected HeLa cells (27) (Fig. 2 and 8) and that the protein is actively imported in an in vitro system (J. M. Petersen, unpublished data). The mutant M(51R) and M(51L) proteins also enter the nucleus both in vivo and in vitro (Fig. 8) (37; unpublished data), showing that Met-51 is not required for nuclear uptake of M protein. It is unclear whether M protein exits the nucleus by diffusion or active transport.
In addition to inhibiting nucleocytoplasmic transport, wild-type M protein was previously reported to inhibit gene expression in cultured cells (5, 6, 13, 42) and transcription in vitro (2, 62). We have not observed an inhibition of transcription by M protein in Xenopus oocytes, but we recognize that oocyte nuclei may be unusual in that they contain large stockpiles of transcription and replication factors (24). In any case, the loss of inhibition of both gene expression and transport upon mutation of Met-51 indicates that a common mechanism is involved. We have proposed (27) that M protein may affect gene expression directly by blocking mRNA export. In addition, inhibition of transport might secondarily affect the import or function of factors that are essential for the assembly of active transcription complexes. However, M protein may use the same mechanism to inactivate different targets that affect either transport or transcription independently. Recent evidence suggests that inhibition of RNA polymerase II transcription by M protein alters the activity of the transcription factor TFIID (62).
Inhibition of transport by M protein, presumably via association with a nuclear component of NPCs, may recapitulate control systems that normally modulate nucleocytoplasmic transport in uninfected cells. For example, the target(s) of M protein could be a component of the NPC, the function of which could be altered during induction of a stress response, reduction of cell growth rate, or progression through the cell cycle (12, 34, 48). Thus, M protein might provide a potent tool for investigation of cellular mechanisms that regulate nuclear transport and transcription. Our current efforts are focused on the identification of the intranuclear components of the NPC that interact with M protein and on elucidation of how inhibition of transport and transcription are linked.
| |
ACKNOWLEDGMENTS |
|---|
We thank Douglas Lyles, Jen Bachorik, and Laura Davis for kindly supplying reagents and Brian Kay for assistance with phage display selection. We also thank Susanne Blaser-Imboden, Matt Bohlman, and Thomas Jensen for technical help and Christopher Trotta and Doreen Glodowski for critical comments on the manuscript.
This work was supported by NIH grant GM30220 and by a DARPA grant (MDA972-97-1-0005) to J.E.D. V.V. was supported by an NIH training grant (GM08349-08). J.M.P. is a Burroughs Wellcome Fund Fellow of the Life Sciences Research Foundation.
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Department of
Biomolecular Chemistry, University of Wisconsin
Madison, 1300 University Ave., Madison, WI 53706-1532. Phone: (608) 262-1459. Fax:
(608) 262-8704. E-mail: dahlberg{at}facstaff.wisc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adam, E. J., and S. A. Adam.
1994.
Identification of cytosolic factors required for nuclear location sequence-mediated binding to the nuclear envelope.
J. Cell Biol.
125:547-555 |
| 2. |
Ahmed, M., and D. S. Lyles.
1998.
Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III.
J. Virol.
72:8413-8419 |
| 3. | Arts, G. J., M. Fornerod, and I. W. Mattaj. 1998. Identification of a nuclear export receptor for tRNA. Curr. Biol. 8:305-314[CrossRef][Medline]. |
| 4. | Bachi, A., I. C. Braun, J. P. Rodrigues, N. Pante, K. Ribbeck, C. von Kobbe, U. Kutay, M. Wilm, D. Gorlich, M. Carmo-Fonseca, and E. Izaurralde. 2000. The C-terminal domain of TAP interacts with the nuclear pore complex and promotes export of specific CTE-bearing RNA substrates. RNA 6:136-158[Abstract]. |
| 5. |
Black, B. L., and D. S. Lyles.
1992.
Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo.
J. Virol.
66:4058-4064 |
| 6. |
Black, B. L.,
R. B. Rhodes,
M. McKenzie, and D. S. Lyles.
1993.
The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly.
J. Virol.
67:4814-4821 |
| 7. | Chen, Z., Y. Li, and R. M. Krug. 1999. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J. 18:2273-2283[CrossRef][Medline]. |
| 8. |
Coulon, P.,
V. Deutsch,
F. Lafay,
C. Martinet-Edelist,
F. Wyers,
R. C. Herman, and A. Flamand.
1990.
Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus.
J. Gen. Virol.
71:991-996 |
| 9. | Dahlberg, J. E., and E. Lund. 1998. Functions of the GTPase Ran in RNA export from the nucleus. Curr. Opin. Cell Biol. 10:400-408[CrossRef][Medline]. |
| 10. | Davis, L. I., and G. Blobel. 1986. Identification and characterization of a nuclear pore complex protein. Cell 45:699-709[CrossRef][Medline]. |
| 11. | Dobbelstein, M., J. Roth, W. T. Kimberly, A. J. Levine, and T. Shenk. 1997. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J. 16:4276-4284[CrossRef][Medline]. |
| 12. |
Feldherr, C. M., and D. Akin.
1991.
Signal-mediated nuclear transport in proliferating and growth-arrested BALB/c 3T3 cells.
J. Cell Biol.
115:933-939 |
| 13. | Ferran, M. C., and J. M. Lucas-Lenard. 1997. The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J. Virol. 71:371-377[Abstract]. |
| 14. | Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj, and R. Lührmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82:475-483[CrossRef][Medline]. |
| 15. |
Follett, E. A.,
C. R. Pringle,
W. H. Wunner, and J. J. Skehel.
1974.
Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus.
J. Virol.
13:394-399 |
| 16. | Fornerod, M., J. van Deursen, S. van Baal, A. Reynolds, D. Davis, K. G. Murti, J. Fransen, and G. Grosveld. 1997. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 16:807-816[CrossRef][Medline]. |
| 17. | Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051-1060[CrossRef][Medline]. |
| 18. |
Fresco, L. D.,
M. G. Kurilla, and J. D. Keene.
1987.
Rapid inhibition of processing and assembly of small nuclear ribonucleoproteins after infection with vesicular stomatitis virus.
Mol. Cell Biol.
7:1148-1155 |
| 19. |
Frishman, D., and P. Argos.
1996.
Incorporation of non-local interactions in protein secondary structure prediction from the amino acid sequence.
Protein Eng.
9:133-142 |
| 20. | Frishman, D., and P. Argos. 1997. Seventy-five percent accuracy in protein secondary structure prediction. Proteins 27:329-335[CrossRef][Medline]. |
| 21. |
Görlich, D.,
M. Dabrowski,
F. R. Bischoff,
U. Kutay,
P. Bork,
E. Hartmann,
S. Prehn, and E. Izaurralde.
1997.
A novel class of RanGTP binding proteins.
J. Cell Biol.
138:65-80 |
| 22. | Grimm, C., E. Lund, and J. E. Dahlberg. 1997. In vivo selection of RNAs that localize in the nucleus. EMBO J. 16:793-806[CrossRef][Medline]. |
| 23. |
Grimm, C.,
E. Lund, and J. E. Dahlberg.
1997.
Selection and nuclear immobilization of exportable RNAs.
Proc. Natl. Acad. Sci. USA
94:10122-10127 |
| 24. | Gurdon, J. B., and W. P. Wickens. 1983. The use of Xenopus oocytes for the expression of cloned genes. Methods Enzymol. 101:370-386[Medline]. |
| 25. |
Hammarskjöld, M. L.,
J. Heimer,
B. Hammarskjöld,
I. Sangwan,
L. Albert, and D. Rekosh.
1989.
Regulation of human immunodeficiency virus env expression by the rev gene product.
J. Virol.
63:1959-1966 |
| 26. | Harlow, E., and D. Lane. 1988. Storing and purifying antibodies, p. 285-318. In E. Harlow, and D. Lanes (ed.), Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, New York, N.Y. |
| 27. |
Her, L.-S.,
E. Lund, and J. E. Dahlberg.
1997.
Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus.
Science
276:1845-1848 |
| 28. | Huber, J., U. Cronshagen, M. Kadokura, C. Marshallsay, T. Wada, M. Sekine, and R. Lührmann. 1998. Snurportin1, an m3G-cap-specific nuclear import receptor with a novel domain structure. EMBO J. 17:4114-4126[CrossRef][Medline]. |
| 29. | Izaurralde, E., U. Kutay, C. von Kobbe, I. W. Mattaj, and D. Görlich. 1997. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J. 16:6535-6547[CrossRef][Medline]. |
| 30. | Jäkel, S., and D. Görlich. 1998. Importin beta, transportin, RanBP5 and RanBP7 mediate nuclear import of ribosomal proteins in mammalian cells. EMBO J. 17:4491-4502[CrossRef][Medline]. |
| 31. |
Kaptur, P. E.,
R. B. Rhodes, and D. S. Lyles.
1991.
Sequences of the vesicular stomatitis virus matrix protein involved in binding to nucleocapsids.
J. Virol.
65:1057-1065 |
| 32. | Kutay, U., E. Izaurralde, F. R. Bischoff, I. W. Mattaj, and D. Gorlich. 1997. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex. EMBO J. 16:1153-1163[CrossRef][Medline]. |
| 33. | Kutay, U., G. Lipowsky, E. Izaurralde, F. R. Bischoff, P. Schwarzmaier, E. Hartmann, and D. Görlich. 1998. Identification of a tRNA-specific nuclear export receptor. Mol. Cell 1:359-369[CrossRef][Medline]. |
| 34. | Liu, Y., S. Liang, and A. M. Tartakoff. 1996. Heat shock disassembles the nucleolus and inhibits nuclear protein import and poly(A)+ RNA export. EMBO J. 15:6750-6757[Medline]. |
| 35. | Lund, E., and P. L. Paine. 1990. Nonaqueous isolation of transcriptionally active nuclei from Xenopus oocytes. Methods Enzymol. 181:36-43[Medline]. |
| 36. |
Lyles, D. S.,
L. Puddington, and B. J. McCreedy, Jr.
1988.
Vesicular stomatitis virus M protein in the nuclei of infected cells.
J. Virol.
62:4387-4392 |
| 37. | Lyles, D. S., and M. O. McKenzie. 1997. Activity of vesicular stomatitis virus M protein mutants in cell rounding is correlated with the ability to inhibit host gene expression and is not correlated with virus assembly function. Virology 229:77-89[CrossRef][Medline]. |
| 38. | Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 65:4248-4254 |